Variaciones en el tamaño plaquetario en pacientes con neoplasias mieloproliferativas

CELLUCI MS.; MARIN OYARZUN CP.; GLEMBOTSKY AC.; GOETTE NP.; LEV PR.; GRODZIELSKI M.; BARONI C.; HELLER PG.; MARTA RF.

CABA

Congreso; Reunión conjunta de sociedades de Biociencias; 2017

Myeloproliferative neoplasms (MPN) comprising essential thrombocythemia (ET), Policythemia vera (PV), and primary myelofibrosis (MF) are frequently associated with thrombotic complications. Current treatments for these entities include hydroxiurea (HU), -interferon (IFNa), anagrelige (Ana) and, especially in MF, the JAK inhibitor, ruxolitinib (Ruxo). Considering that platelet size is associated with platelet reactivity, being large platelets more active and linked to thrombotic events, in this study we investigated possible differences in platelet size in 69 MPN patients grouped according to their diagnosis, mutational status and treatment.Taking into account that cell counters underestimate platelet volumen, platelet diameter was measured by optical microscopy on May-Grünwald-Giemsa?stained blood films and by software image analysis. At least 100 platelets were evaluated in each patient, and the maximum diameter (MPD) of each platelet was recorded. Normal values, established in 26 control samples were 2.55 m(2.24-2.98) (median, range). MPN patients had increased platelet size (t test, p=0.0347). No differences in MPD were seen when patients were grouped according to their diagnosis. Platelets from patients without treatment (n=24) as well as those treated with IFNa (n=8), Ana (n=10) or Ruxo (n=7) had larger platelets than normal controls and patients treated with HU (n=22) (Tukey´s test, p